• Faisal Alsayegh, Aisha Fakeir, Salah Alhumood, Kefaya Abdumalek, Hatem Matar, Isaac Samaul, Narayanan Nampoory, Housam Kabalawi, and Shaker A Mousa.
• Faculty of Medicine, Kuwait University, and Department of Medicine, Mubarak Al-Kabeer Hospital.
• Clin. Appl. Thromb. Hemost. 2009 Mar 1;15(2):225-32.

AbstractA retrospective analysis is described to assess the effects of using recombinant activated factor VII to control bleeding in a series of patients who had failed to respond to conventional hemostatic measures. In all, 18 patients (aged 16-65 years) with a range of conditions resulting in bleeding refractory to conventional methods of control were treated with recombinant activated factor VII (60-120 Amicrog/kg; 1-4 doses). The effects of recombinant activated factor VII on bleeding were noted together with the patients' transfusion requirements and hematological parameters. Administration of recombinant activated factor VII successfully stopped bleeding in 17 of the 18 patients. Therapy with recombinant activated factor VII significantly decreased transfusion requirements for packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate compared with pretreatment values along with significant improvement in hemostasis. In various serious bleeding situations, treatment with recombinant activated factor VII may effectively arrest bleeding, which has remained refractory to conventional methods of control.

29 keywords...

hide…